PROFESSOR OF MEDICINE

Size: px

Start display at page:

Download "PROFESSOR OF MEDICINE"

Madison Poole
6 years ago
Views:

1 PRINCIPAL INVESTIGATOR: WHITE, WILLIAM B BIOGRAPHICAL SKETCH Provide the following information for the key personnel and consultants and collaborators. Begin with the principal investigator/program director. Photocopy this page for each person. NAME POSITION TITLE WILLIAM B. WHITE, M.D. PROFESSOR OF MEDICINE EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) YEAR FIELD INSTITUTION AND LOCATION DEGREE CONFERRED OF STUDY Emory University, Atlanta, GA B.S Biology Medical College of Georgia, Augusta, GA M.D Medicine PROFESSIONAL EXPERIENCE Resident in Medicine, University of Connecticut Health Center, Farmington Fellow in Medicine/Clinical Pharmacology, University of Connecticut School of Medicine Assistant Professor, Medicine, University of Connecticut School of Medicine Associate Professor of Medicine, University of Connecticut School of Medicine Research Visiting Professor in Cardiovascular Medicine, Section of Cardiology, University of Bergen School of Medicine, Bergen, Norway 1991-present Professor of Medicine (with tenure), University of Connecticut School of Medicine Chief, Division of Internal Medicine, University of Connecticut Health Center 1997-present Chief, Division of Hypertension and Clinical Pharmacology, University of Connecticut Health Center, Farmington 2000-present Medical director, Clinical Trials Unit, University of Connecticut Health Center 2003-present Faculty Member, Pat and Jim Calhoun Cardiology Center, University of Connecticut ACADEMIC ACTIVITIES AND AWARDS 1984 American College of Physicians (Fellow) 1982 American Heart Association (Fellow, Council for High Blood Pressure Research) Editorial Board, Clinical Pharmacology and Therapeutics (CPT) Editorial Board, Journal of Hypertension Editorial Board, American Journal of Cardiology (AJC) Editorial Board, Journal of Human Hypertension Editorial Board, American Journal of Hypertension (AJH) Editorial Board, American Journal of Medicine (AJM) Editorial Board, Ethnicity and Disease Editorial Board, Heart Disease Editorial Board, Journal of Clinical Hypertension (JCH) Editorial Board, Hypertension (American Heart Association) Editorial Board, Journal of the American Society of Hypertension (JASH) Site Committees, SCOR grant, Hypertension Section, NHLBI 1993 American Board of Clinical Pharmacology, board certified Study Section, Special Emphasis Panel, AHCPR, NIH Editor-in-Chief, Blood Pressure Monitoring (Lippincott-Williams & Wilkins) Research committee, Clinical & Community Research, Donaghue Foundation American Society of Hypertension Specialist in Clinical Hypertension (certificate) Chair, Study Section, Donaghue Medical Research Foundation, Hartford, Connecticut American Society of Hypertension, Board of Directors 1

2 RESEARCH PROJECTS ONGOING OR COMPLETED DURING THE LAST 3-4 YEARS : PRINCIPAL INVESTIGATOR 1. Brain changes and vascular risk factors causing impaired mobility. National Institute of Aging (NIH), R01 AG , March (co-principal investigator with L Wolfson, Department of Neurology at UCHC). 2. Blood pressure variability in African-American patients with essential hypertension Catherine and Patrick Donaghue Medical Research Foundation (Hartford, Connecticut) - the 24 hour variablity of blood pressure and its relationship to vascular target organ disease ( ) 3. Controlled Onset Verapamil Investigation for Cardiovascular Endpoints (CONVINCE) - Chairman, Endpoints Committee and Member, Executive Steering Committee - 17,000+ patient trial to assess the impact of a chronotherapy versus standard of care therapy on cardiovascular endpoints ( ) 4. Pathophysiology of nocturnal blood pressure variability - Investigator: George A. Mansoor, M.D. Mentor William B. White, M.D. National Institutes of Health (K23 award) - a collaboration to develop improved paradigms for the assessment of nocturnal hypertension ( ) 5. Clinical outcomes in pregnancy hypertension Catherine and Patrick Donaghue Medical Research Foundation predictive value of office, self- and ambulatory BP on pre-eclampsia, maternal and fetal outcomes ( ) 6. Effects of ascorbic acid on vascular function. Catherine and Patrick Donaghue Medical Research Foundation (Hartford, Connecticut) Effects of selective aldosterone blockade (eplerenone) in hypertension and vascular disease, including isolated systolic hypertension, vascular compliance, protein excretion, and low renin, high aldosterone states Searle/Pharmacia Research & Development, Peapack, NJ, 1997 to Investigator-initiated: Importance of selective aldosterone blockade in the treatment of resistant hypertension Pfizer Central Research, New York, NY Investigator-iniitated: Impact of beta-blockade and calcium antagonist on circadian variability of rate-pressure product. Astra Zeneca, Wilmington, Delaware: Investigator-initiated: Meta-analysis of cardiovascular events in the controlled clinical trial database of celecoxib PI (with Jeffrey Borer, MD, Phil Gorelick, MD and Ken Verburg, PhD) Pfizer Research (Inflammation and Pain), Ann Arbor, MI Publications (selected from 330 articles) WHITE WB. Assessment of patients with office hypertension by 24-hour noninvasive ambulatory blood pressure monitoring. Arch Intern Med 1986; 146: Smith VE, WHITE WB, Meeran MK, Karimeddini MK. Improved left ventricular filling accompanies reduced left ventricular mass during therapy of hypertension. J Am Coll Cardiol 1986; 8: WHITE WB, Radford MJ, Gonazalez FM, Weed SG, McCabe EJ. Selective dopamine-1 agonist therapy in severe or accelerated hypertension. J Am Coll Cardiol 1988; 11: WHITE WB, Schulman P, Dey HM, Katz AM. Effects of age and 24-hour blood pressure on rapid left ventricular filling. Am J Cardiol 1989; 63: WHITE WB, Schulman P, McCabe EJ, Dey HM. Average daily blood pressure, not office blood pressure, determines cardiac function in patients with hypertension. JAMA 1989; 261: WHITE WB, Schulman P, Smith VE. Regression of left ventricular mass is accompanied by improved left ventricular filling following therapy with metoprolol in patients with essential hypertension. Am Heart J 1989; 117: WHITE WB, Morganroth J. Usefulness of ambulatory monitoring of blood pressure in assessment of antihypertensive therapy. Am J Cardiology 1989; 63: National High Blood Pressure Coordinating Committee (Sheps SG, Krakoff L, Pickering TG, Weber MA, WHITE WB, Zachariah P). National high blood pressure education program working group report on ambulatory blood pressure monitoring. Arch Intern Med 1990; 150: WHITE WB, Schulman P, Dey HM, Katz A. Effects of age and 24-hour blood pressure on rapid left ventricular filling. Am J Cardiol 1989; 63:

3 WHITE WB, Dey HM, Schulman P. Assessment of the average daily blood pressure load as a determinant of cardiac function in patients with mild to moderate hypertension. Am Heart J 1989; 118: WHITE WB, Lund-Johansen P, Omvik P. Assessment of four ambulatory blood pressure monitors and measurements by clinicians versus intraarterial blood pressure at rest and during exercise. Am J Cardiol 1990; 65: WHITE WB. A Physician's Guide to Hypertension. Marcel-Dekker, New York, 1990, 223 pp. WHITE WB, Berson A, Robbins C, Jamieson M, Prisant M, Roccella E, Sheps SG. A National Standard for measurement of resting and ambulatory blood pressures with automated sphygmomanometers. Hypertension 1993; 21: Grin JM, McCabe EJ, WHITE WB. Management of hypertension after ambulatory blood pressure monitoring. Ann Intern Med 1993; 118: WHITE WB, Lund-Johansen P, Weiss S, et al. The relationships between casual and ambulatory blood pressure and central hemodynamics in essential hypertension. J Hypertension 1994; 12: WHITE WB, Mansoor GA, Singh S, Ramsby G, Ruby ST. Determinants of long-term blood pressure response to renal revascularization. J Vasc Med Biol 1994; 5: WHITE WB, Anders RJ, MacIntyre JM, Black HR, Sica D. A novel delivery system of verapamil for nocturnal dosing in patients with systemic hypertension. Am J Cardiol 1995; 76: Rehman F, Mansoor GA, WHITE WB. Inappropriate prescribing habits for oral nifedipine capsules in hospitalized patients. American Journal of Hypertension 1996; 9: WHITE WB, Black HR, Mehrotra D, Fakouhi TD. Effects of COER-verapamil on circadian variation of BP (dippers vs nondippers). Am J Cardiol 1997; 78: Mansoor GA, WHITE WB. Circadian blood variation in hypertensive patients with primary hyperaldosteronism. Hypertension 1998; 31: WHITE WB, Asmar R, Imai Y, Mansoor GA, Padfield P, Thijs L, Waeber B. Task Force VI: Self monitoring of the blood blood pressure. Blood Pressure Monitoring 1999; 4: WHITE WB. Benefits of treating older patients with hypertension. Archives of Internal Medicine 2000; 160: Mansoor GA, WHITE WB, McCabe EJ, Giacco SL. The relationship of electronically-monitored physical activity to blood presssure, heart rate and the circadian blood pressure profile. American Journal of Hypertension 2000; 13:262-. WHITE WB, Prisant LM, Wright J. Management of patients with hypertension and diabetes mellitus: advances in the evidence for intensive treatment. American Journal of Medicine 2000; 108: WHITE WB. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics (Editor and author of multiauthored book). Humana Press, Inc, Totowa, New Jersey, November 2000; 300 pp. WHITE WB, Johnson M, Elliott WJ, Black HR. Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension. Journal of Human Hypertension 2001; 15: Peixoto AJ, Santos SFF, Mendes RB, Crowley ST, Malonado R, Orias M, Mansoor GA, WHITE WB. Reproducibility of ambulatory blood pressure monitoring in hemodialysis patients. American Journal of Kidney Disease 2000; 36: WHITE WB, Johnson M, Elliott WJ, Black HR, Sica DA. Impact of age and gender on the efficacy and tolerability of antihypertensive therapy. American Journal of Hypertension : WHITE WB. The systolic blood pressure versus pulse pressure controversy. American Journal of Cardiology 2001; June 1; 87(11): Verdecchia P, Staessen JA, WHITE WB, Imai Y, O Brien E. Properly defining white-coat hypertension. European Heart Journal 2002; 23: WHITE WB, Faitch G, Whelton A, Verburg K, Ridge N, Lefkowith JL, Geis S. Effects of celecoxib versus ibuprofen and diclofenac on cardiovascular thromboembolic events. American Journal of Cardiology 2002; 89: White WB, Kent J, Taylor A, Verburg K, Lefkowith J, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertnsive patients on ACE inhibitors. Hypertension 2002; 39: WHITE WB. Clinical utility of ambulatory blood pressure: perspectives for national insurance coverage. Blood Pressure Monitoring 2002: 7: WHITE WB, Sica DA, Calhoun D, Mansoor GA, Anders RJ. Preventing increases in early morning blood pressure, heart rate, and the rate-pressure product with controlled onsent extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. American Heart Journal 2002; 144: Whelton A, WHITE WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > 65 years of age with systemic hypertension and osteoarthritis. American Journal of Cardiology 2002; 90: Meredith PA, Elliott HL, WHITE WB. Hypertension and Related Disorders, Mosby Books, 2003, 152 pp. 3

4 Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, WHITE WB, et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) Trial. JAMA 2003; 289: WHITE WB, Duprez D, St. Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: WHITE WB. Ambulatory blood pressure monitoring in clinical practice. The New England Journal of Medicine 2003; 348: WHITE WB, Saunders EJ. The comparative efficacy and safety of nisoldipine extended-release and amlodipine (CESNA-III) in African American patients with hypertension. American Journal of Hypertension ; 2003; 16: WHITE WB, Faich G, Borer J, Makuch R. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase inhibitor celecoxib. American Journal of Cardiology 2003; 92: WHITE WB, Carr AA, Krause S, et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. American Journal of Cardiology 2003; 92: WHITE WB, Larocca GM. Improving the utility of the nocturnal hypertension definition by using absolute sleep blood pressure rather than the dipping proportion, American Journal of Cardiology 2003; 92: WHITE WB, LaCourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: Impact on the early morning period. American Journal of Hypertension 2004; 17: WHITE WB. Relevance of blood pressure variation in the circadian onset of cardiovascular events. Journal of Hypertension 2003; 21 (suppl 6): WHITE WB, Lacourciere Y, Gana T, et al. The effects of graded-release diltiazem versus ramipril dosed at bedtime on the early-morning blood pressure, heart rate, and the rate-pressure product. American Heart Journal 2004; 148: WHITE WB, Strand V, Roberts R, Whelton A. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal anti-inflammatory agents and placebo on cardiovascular thrombotic events in patients with art.hritis. American Journal of Therapeutics 2004; 11: WHITE WB. Hypertension associated with therapies to treat arthritis and pain (editorial). Hypertension 2004; 44: Mansoor GA, WHITE WB. Self-measured home blood pressure in predicting ambulatory hypertension. American Journal of Hypertension. 2004;17: Sowers J, WHITE WB et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal antiinflammatory therapy on 24-hour blood pressure in hypertensive patients with osteoarthritis and type 2 diabetes mellitus Archives of Internal Medicine 2005; 165(2):161-8 WHITE WB. Update on the drug treatment of hypertension in patients with cardiovascular diseases. American Journal of Medicine 2005; 118: WHITE WB, Pitt B, Preston R, Hanes V. Antihypertensive effects of drospirenone with 17-beta estradiol, a novel hormone treatment in post-menopausal women with stage 1 hypertension. Circulation 2005; 112: WHITE WB, Giles T, Bakris GL, Neutel JM, Davidai G, Weber MA. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. American Heart Journal 2006; 151: WHITE WB. Expanding the use of ambulatory blood pressure monitoring for the diagnosis and management of patients with hypertension. Hypertension 2006; 47: WHITE WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-betaestradiol, in postmenopausal women with hypertension. Hypertension ;48(2): Labinson PT, WHITE WB, Tendler BE, Mansoor GA. Primary hyperaldosteronism associated with hypertensive emergencies. Am J Hypertens. 2006;19(6): WHITE WB, West C, Borer J, Gorelick P, Pan S, Weiner E, Verburg K. Risk of cardiovascular events in patients Receiving Celecoxib: A Meta-analysis of Randomized Clinical Trials. American Journal of Cardiology 2007; 99: WHITE WB. The cardiovascular effects of the cyclooxygenase inhibitors. Hypertension 2007; 49: Peixoto A, WHITE WB. Circadian blood pressure: Clinical implications based on the pathophysiology of its variability. Kidney International 2007; in press WHITE WB, Mallareddy M. Cardiovascular effects of the novel progestin, drospirenone. Drugs

5 WHITE WB. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics (Editor and author). Humana Press, Inc, Totowa, New Jersey, 2 nd edition. April 2007; 400 pp.. 5

The incidence of transient myocardial ischemia,

The incidence of transient myocardial ischemia, AJH 1999;12:50S 55S Heart Rate and the Rate-Pressure Product as Determinants of Cardiovascular Risk in Patients With Hypertension William B. White Inability to supply oxygen to the myocardium when demand